CBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
CRESCENT BIOPHARMA, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$12.36+0.52 (+4.39%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Operating margin
-1407.5%−900.7 pts over 5 years
Net margin
-1419.6%−917.5 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | – | +424.9% | +1.3% | -6.0% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -84.0% | -36.1% | -164.2% | |
| Return on assets | -70.0% | -32.8% | -111.6% | |
| Current ratio | 6.40 | 11.13 | 6.56 | |
| Debt to equity | – | – | 0.00 | |
| Capex to revenue | 3806.5% | 0.7% | 8.5% | |
| Diluted shares | 21M | 46M | – |
Where the cash went
Fiscal 2021 to 2025, five years combined
Crescent Biopharma generated $241.46M from operations and spent $1.05M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$241.46M
Used
$1.05M
Capital expenditure$1.05M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-1419.6%
×Asset turnover0.08×
×Equity multiplier1.47×
=Return on equity, FY2025-164.2%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -1419.6% | 0.08× | 1.47× | -164.2% |
| FY2023 | -368994.2% | 0.00× | 1.19× | -90.7% |
| FY2022 | -62251.7% | 0.00× | 1.17× | -75.0% |
| FY2021 | -5469.0% | 0.01× | 1.13× | -60.5% |
| FY2020 | -502.1% | 0.07× | 1.10× | -36.1% |
| FY2016 | -171945.1% | 0.00× | 1.20× | -84.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$153.94M
- Cash generatingOperating cash flow above zero-$71.53M
- Return on assets improvedROA up on the prior year-83.6% → -432.2%
- Earnings backed by cashOperating cash flow above net income-$71.53M vs -$153.94M
- Less leverageLong-term debt to assets fell105.2% → 0.0%
- Better liquidityCurrent ratio rose3.62 → 6.56
- No dilutionShare count did not rise64M → –
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → 0.30